Earlier ALT normalization during antiviral treatment tied to reduced HCC risk in CHB
Earlier normalization of serum alanine aminotransferase (ALT) levels in patients with chronic hepatitis B (CHB) who initiated treatment with entecavir or tenofovir correlates with a proportionally lower risk of hepatocellular carcinoma (HCC), regardless of fatty liver or cirrhosis at baseline and on-treatment virological response (VR), according to a recent study.
